Allergy Therapeutics cleared by FDA to start testing peanut allergy vaccine

The FDA has cleared Allergy Therapeutics’s application to start a phase I trial with a vaccine for peanut allergies, and the company can now initiate the study in the first half of 2022.

Photo: Patrick Sison/AP/Ritzau Scanpix

The race to come first to the billion-dollar food allergy market is heating up.

UK-based firm Allergy Therapeutics, which is listed on the London stock exchange, has announced in a press release that the US Food and Drug Administration (FDA) has given the company the green light to start a phase 1 trial of its peanut allergy vaccine in the US.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs